Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy

Karasu, Bugra; artunay, ozgur

Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy

Buğra KARASU, (Beyoğlu Eğitim ve Araştırma Hastanesi, Göz Doktoru, Beyoğlu, Türkiye)

Özgür ARTUNAY (Beyoğlu Eğitim ve Araştırma Hastanesi, Beyoğlu, Türkiye)

Retina-Vitreus

0 0

Yıl: 2021 Cilt: 30 Sayı: 1 Sayfa Aralığı: 47 - 54 Metin Dili: İngilizce İndeks Tarihi: 17-05-2022

Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy

Öz:

Purpose: To compare visual and anatomical results of anti- vascular endothelial growth factor (VEGF) combined with photodynamic therapy (PDT) versus only performing anti- VEGF therapy in eyes with polypoidal choroidal vasculopathy (PCV). Materials and Methods: Retrospective review of 60 PCV patients who underwent anti- VEGF combined with PDT (Group 1) or solely performing anti- VEGF therapy (Group 2) were enrolled. The best corrected visual acuity (BCVA), central macular thickness (CMT), presence of subretinal fl uid (SF) were compared among the groups during the follow-up periods at baseline, 1st month, 3rd month, 6th month, 9th month, 12th month,18th month, 24th month and fi nal visit, respectively. Results: The mean age of the patients was 71.96 ± 8.50 years (range, 52-88 years), and the mean follow-up period was 53.83 ± 14.86 (range, 20-85 months). The mean number of injections was observed as 10.56 ± 1.88 (range, 7 -15) in the fi rst group and 11.83 ± 2.61 (range, 7 - 17) in the second group, respectively (p = 0.039). In group 1, BCVA decreased from the logarithm of the minimum angle resolution (log MAR) of 0.59 ± 0.39 to 0.70 ± 0.41 log MAR in the fi nal examination (p = 0.016), CMT initial 355.562 ± 95.54 μm decreased from to 296,76 ± 105,03 μm at the last examination (p <0.001), the presence of SRF showed a statistically signifi cant decrease in follow-up periods compared to the initial period (p <0.001). In group 2, BCVA decreased from initial 0.65 ± 0.61 log MAR to 0.82 ± 0.56 log MAR in the fi nal examination (p <0.001), CMT decreased from baseline 372.60 ± 114.21 μm to 287.06 ± 64.32 μm at the last examination (p = 0.001), the presence of SF showed a statistically signifi cant decrease in follow-up periods compared to the initial period (p <0.001). In the last examination, there was no statistically signifi cant difference between the groups in terms of presence of SF (p = 0.305). Conclusion: Both full-dose PDT combined with anti-VEGF and only anti-VEGF applications are effective in the treatment of PCV. There was no signifi cant difference in visual or anatomical results among the two groups. However, we observed that full dose PDT administration combined with anti-VEGF reduces the need for anti-VEGF usage.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik

1. Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100-10, 1995.
2. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 32 ;1:1-8, 2012.
3. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 115:478-85, 1997.
4. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 133: 639-648, 2002.
5. Koh AH; Expert PCV Panel, Chen LJ, Chen SJ, et al. Polypoidal choroidal vasculopathy: Evidence-based guidelines for clinical diagnosis and treatment. Retina 2013;33:686-716.
6. Romano MR, Cipollone U, Semeraro F, et al. Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: oneyear followup. Clin Ophthalmol 2010; 4:1237-1241.
7. Sato T, Kishi S, Matsumoto H, et al. Combined photodynamic therapy with verteporfi n and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010;149(6):947-954.
8. Gomi F, Sawa M, Wakabayashi T, et al. Effi cacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010;150(1):48-54.
9. Zuo C, Wen F, Li J, et al. Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Doc Ophthalmol 2009;119(1):29-36.
10. Moon SW, Kim MS, Kim ES, et al. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy. Ophthalmologica 2011;225(3):169-175.
11. Ruamviboonsuk P, Tadarati M, Vanichvaranont S, et al. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol 2010;94(8):1045- 1051.
12. Kurashige Y, Otani A, Sasahara M, et al.Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008;146(4):513-519.
13. Tsuchiya D, Yamamoto T, Kawasaki R, et al. Twoyear visual outcomes after photodynamic therapy in agerelated macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 2009; 29(7):960-965.
14. Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008;28(5):717-722.
15. Milanesi C, Biolo R, Reddi E, et al. Ultrastructural studies on the mechanisms of photodynamic therapy of tumors. Pho- tochem. Photobiol 1987;46: 675-81.
16. Henderson BW, Dougherty TJ. How does PDT work? Photochem Photobiol 1992;55: 145-57.
17. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1995; 11 3:8 10-8 18.
18. Schmidt-Erfurth U, Hasan T, Gragoudas E, et al. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994; 101: 1953-61.
19. Wang F, Yuan Y, Wang L, et al. One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial. J Ophthalmol 2019 Oct 10;2019: 7530458.
20. Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH. Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res 2013; 37:182-99.
21. Lai TY, Chan WM, Liu DT, et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:661-6.
22. Gomi F, Sawa M, Sakaguchi H, et al. Effi cacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70-3.
23. Song JH, Byeon SH, Lee SC, et al. Short term safety and effi cacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica 2009;223:85-92.
24. Pai SA, Shetty R. Sequential therapy with intravitreal bevacizumab and photodynamic therapy for idiopathic polypoidal choroidal vasculopathy. Acta Ophthalmol 2009; 87:806-7.
25. Lee SY, Kim JG, Joe SG, et al. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 2008; 22:92-9.
26. Tsujikawa A, Ooto S, Yamashiro K, et al. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol 2010;54:310-9.
27. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2010;94:297-301.
28. Rouvas AA, Papakostas TD, Ntouraki A, et al. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina 2011;31:464-74.
29. Cheng CK, Peng CH, Chang CK, et al. One-year outcomes of intravitreal bevacizumab (Avastin) therapy for polypoidal choroidal vasculopathy. Retina 2011; 31:846-56.
30. Cho M, Barbazetto IA, Freund KB. Refractory neovascular agerelated macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148: 70-8.
31. Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002; 22:529-35.
32. Chan WM, Lam DS, Lai TY, et al.Photodynamic therapy with verteporfi n for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004;111:1576-84.
33. Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007;144: 7-14
34. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008;115:141-6.
35. Silva RM, Figueira J, Cachulo ML, et al. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfi n. Graefes Arch Clin Exp Ophthalmol 2005;243:973-9.
36. Yamashiro K, Tsujikawa A, Nishida A, et al. Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy. Jpn J Ophthalmol 2008;52:457-62.
37. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, et al. Infl uence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44:4473-80.
38. Koh A, Lee WK, Chen LJ, et al. EVEREST study: Effi cacy and safety of verteporfi n photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32: 1453-64.
39. Neslihan Astam, Emin Özmert, Figen Batioğlu. Results of Photodynamic Therapy/Combination Therapy for Retinal Angiomatous Proliferation and Polypoidal Choroidal Vasculopathy in Age-Related Macular Degeneration. Journal of Retina- Vitreus 2007;15:2.
40. Gomi F, Oshima Y, Mori R, et al. Fujisan Study Group: Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan Study. Retina 2015; 35: 1569-76.
41. Hikichi T, Higuchi M, Matsushita T, et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 2012; 154: 117-24.
42. Saito M, Kano M, Itagaki K, et al. Switching to intravitreal afl ibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. Retina 2014; 34: 2192-201.
43. Yamamoto A, Okada AA, Kano M, et al. One year results of intravitreal afl ibercept for polypoidal choroidal vasculopathy. Ophthalmology 2015; 122: 1866-72.
44. Lee WK, Iida T, Ogura Y, et al. PLANET Investigators. Effi cacy and Safety of Intravitreal Afl ibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol 2018;1;136:786-93.

APA	Karasu B, artunay o (2021). Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. , 47 - 54.
Chicago	Karasu Bugra,artunay ozgur Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. (2021): 47 - 54.
MLA	Karasu Bugra,artunay ozgur Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. , 2021, ss.47 - 54.
AMA	Karasu B,artunay o Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. . 2021; 47 - 54.
Vancouver	Karasu B,artunay o Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. . 2021; 47 - 54.
IEEE	Karasu B,artunay o "Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy." , ss.47 - 54, 2021.
ISNAD	Karasu, Bugra - artunay, ozgur. "Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy". (2021), 47-54.

APA	Karasu B, artunay o (2021). Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. Retina-Vitreus, 30(1), 47 - 54.
Chicago	Karasu Bugra,artunay ozgur Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. Retina-Vitreus 30, no.1 (2021): 47 - 54.
MLA	Karasu Bugra,artunay ozgur Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. Retina-Vitreus, vol.30, no.1, 2021, ss.47 - 54.
AMA	Karasu B,artunay o Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. Retina-Vitreus. 2021; 30(1): 47 - 54.
Vancouver	Karasu B,artunay o Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy. Retina-Vitreus. 2021; 30(1): 47 - 54.
IEEE	Karasu B,artunay o "Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy." Retina-Vitreus, 30, ss.47 - 54, 2021.
ISNAD	Karasu, Bugra - artunay, ozgur. "Comparison of Visual and Anatomical Outcomes of Anti- Vascular Endothelial Growth Factor Combined with Photodynamic Therapy Versus Solely Performing Anti- Vascular Endothelial Growth Factor Therapy in Eyes with Polypoidal Choroidal Vasculopathy". Retina-Vitreus 30/1 (2021), 47-54.